RESAntiPath

—

TARPSWG – R2006

Study Period: January 1st 2017 – January 31st 2020

Specific dataset (not included in RESAR):

- None

Deadline for data transfer to Milan:

immediately after DUF signature

Prepare data since now!

ACTIONS:

- Be prepared for to signed Framework Agreement (if not already done)

- DUF will be circulated in early 2022

1. STUDY TITLE
ANTICIPATED ORGANS RESECTION AND PATHOLOGIC INFILTRATION - RESAntiPath

2. PRINCIPAL INVESTIGATOR
PI   Marco Fiore, Milan
Co-PI   Dirk Strauss, London

3. STATUS
Closed to opt in

4. COLLABORATIVE
22 centers opted in

PRIMARY OUTCOME

- Rate and type of microscopic organ invasion according to
    - Histotype
    - LPS subtype

SECONDARY OUTCOMES

- Type of organ resected according to
    - Histotype
    - Tumor Size

- Predictive value of (surgeon's) radiology assessment

TARPSWG- R2006 RESAntiPath

	Institution	City	Framework Agreement		Institution	City	Framework Agreement
1	Netherlands Cancer Institute	Amsterdam	To be done	12	Fondazione IRCCS Istituto Nazionale Tumori	Milan	29-ott-20
2	Winship Cancer Institute, Emory University	Atlanta	To be done	13	McGill University	Montreal	To be done
3	Hospital San Pau	Barcelona	To be done	14	Ludwig Maximilian University	Munich	To be done
4	Queen Elizabeth Hospital Birmingham	Birmingham	29-ott-20	15	The Ottawa Hospital	Ottawa	29-ott-20
5	DFCI-BWH	Boston	29-ott-20	16	Institut Curie	Paris	To be done
6	Candiolo Cancer Institute	Candiolo	To be done	17	Campus Biomedico	Roma	To be done
7	The Ohio State University	Columbus	29-ott-20	18	Humanitas	Rozzano	To be done
8	Mayo Clinic	Jacksonville	To be done	19	Royal Prince Alfred Hospital	Sydney	To be done
9	Leiden University Medical Center	Leiden	To be done	20	Moffitt Cancer Center	Tampa	To be done
10	Royal Marsden Hospital	London	To be done	21	Tel-Aviv Sourasky Medical Center	Tel-Aviv	To be done
11	Peter MacCallum Cancer Center	Melbourne	29-ott-20	22	NCC Tokyo	Tokyo	To be done

Contacts

marco.fiore@istitutotumori.mi.it